EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Centralized Quality Assurance of Stereotactic Body Radiation Therapy for the Veterans Affairs Cooperative Studies Program Study Number 2005: A Phase 3 Randomized Trial of Lung Cancer Surgery or Stereotactic Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer (VALOR)

Timothy A Ritter, Robert D Timmerman, Hena I Hanfi, Hairong Shi, Matthew K Leiner, Hua Feng, Vicki L Skinner, Lisa M Robin, Cheryl Odle, Gabriella Amador, Tom Sindowski, Amanda J Snodgrass und 9 weitere

Practical Radiation Oncology · 2025

DOI: 10.1016/j.prro.2024.07.010 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Practical Radiation Oncology, 2025. Verfasst von Timothy A Ritter und 20 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Service, Central Virginia Veterans Affairs Health Care System, Richmond, Virginia; Department of Radiation Oncology, Division of M…. Hauptthemen laut MEDLINE: Radiosurgery, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Quality Assurance, Health Care. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: US Department of Veterans Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The phase 3 Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy study implemented centralized quality assurance (QA) to mitigate risks of protocol deviations. This report summarizes the quality and compliance of the first 100 participants treated with stereotactic body radiation therapy (SBRT) in this study. METHODS AND MATERIALS: A centralized QA program was developed to credential and monitor study sites to ensure standard-of-care lung SBRT treatments are delivered to participants. Requirements were adapted from protocols established by the National Cancer Institute's Image and Radiation Oncology Core, which provides oversight for clinical trials sponsored by the National Cancer Institute's National Clinical Trials Network. RESULTS: The first 100 lung SBRT treatment plans were reviewed from April 2017 to October 2022. Tumor contours were appropriate in all submissions. Planning target volume (PTV) expansions were less than the minimum 5 mm requirement in 2% of cases. Critical organ-at-risk structures were contoured accurately for the proximal bronchial tree, trachea, esophagus, spinal cord, and brachial plexus in 75%, 92%, 100%, 100%, and 95% of cases, respectively. Prescriptions were appropriate in 98% of cases; 2 central tumors were treated using a peripheral tumor dose prescription while meeting organ-at-risk constraints. PTV V100% (the percentage of target volume that receives 100% or more of the prescription) values were above the protocol-defined minimum of 94% in all but 1 submission. The median dose maximum (Dmax) within the PTV was 125.4% (105.8%-149.0%; SD ± 8.7%), where values reference the percentage of the prescription dose. High-dose conformality (ratio of the volume of the prescription isodose to the volume of the PTV) and intermediate-dose compactness [R50% (ratio of the volume of the half prescription isodose to the volume of the PTV) and D2cm (the maximum dose beyond a 2 cm expansion of the PTV expressed as a percentage of the prescription dose)] were acceptable or deviation acceptable in 100% and 94% of cases, respectively. CONCLUSIONS: The first 100 participants randomized to SBRT in this study were appropriately treated without safety concerns. A response to the incorrect prescriptions led to preventative measures without further recurrences. The program was developed in a health care system without prior experience with a centralized radiation therapy QA program and may serve as a reference for other institutions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryLung NeoplasmsCarcinoma, Non-Small-Cell LungQuality Assurance, Health CareHumansUnited StatesRadiotherapy Planning, Computer-AssistedMaleUnited States Department of Veterans AffairsRadiotherapy DosageFemale

Autor:innen und Institutionen

  • Radiation Oncology Service, Central Virginia Veterans Affairs Health Care System, Richmond, Virginia; Department of Radiation Oncology, Division of Medical Physics, Virginia Commonwealth University, Richmond, Virginia.…
  • Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Research Service, Central Virginia Veterans Affairs Health Care System, Richmond, Virginia.
  • Veterans Affairs Cooperative Studies Program, Hines, Illinois.
  • Radiation Oncology Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California.
  • Veterans Affairs Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, New Mexico; University of New Mexico College of Pharmacy, Albuquerque, New Mexico.

Förderung

  • US Department of Veterans Affairs

Zitieren

APA

Ritter, T. A., Timmerman, R. D., Hanfi, H. I., Shi, H., Leiner, M. K., Feng, H., Skinner, V. L., Robin, L. M., Odle, C., Amador, G., Sindowski, T., Snodgrass, A. J., Huang, G. D., Reda, D. J., Slatore, C., Sears, C. R., Cornwell, L. D., Karas, T. Z., Harpole, D. H., …, & Moghanaki, D. (2025). Centralized Quality Assurance of Stereotactic Body Radiation Therapy for the Veterans Affairs Cooperative Studies Program Study Number 2005: A Phase 3 Randomized Trial of Lung Cancer Surgery or Stereotactic Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer (VALOR). Practical Radiation Oncology. https://doi.org/10.1016/j.prro.2024.07.010

Vancouver

Ritter TA, Timmerman RD, Hanfi HI, Shi H, Leiner MK, Feng H, et al. Centralized Quality Assurance of Stereotactic Body Radiation Therapy for the Veterans Affairs Cooperative Studies Program Study Number 2005: A Phase 3 Randomized Trial of Lung Cancer Surgery or Stereotactic Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer (VALOR). Practical Radiation Oncology. 2025. doi:10.1016/j.prro.2024.07.010

BibTeX
@article{Ritter2025,
  author = {Ritter, Timothy A and Timmerman, Robert D and Hanfi, Hena I and Shi, Hairong and Leiner, Matthew K and Feng, Hua and Skinner, Vicki L and Robin, Lisa M and Odle, Cheryl and Amador, Gabriella and Sindowski, Tom and Snodgrass, Amanda J and Huang, Grant D and Reda, Domenic J and Slatore, Christopher and Sears, Catherine R and Cornwell, Lorraine D and Karas, Tomer Z and Harpole, David H and Palta, Jatinder and Moghanaki, Drew},
  title = {Centralized Quality Assurance of Stereotactic Body Radiation Therapy for the Veterans Affairs Cooperative Studies Program Study Number 2005: A Phase 3 Randomized Trial of Lung Cancer Surgery or Stereotactic Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer (VALOR)},
  journal = {Practical Radiation Oncology},
  year = {2025},
  doi = {10.1016/j.prro.2024.07.010}
}
Kostenlos starten →